secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seaport Therapeutics, Inc. (SPTX)
CIK:        0002042347
Form:       8-K
Filed at:   2026-08-03T11:03:03+00:00
Accession:  0001193125-26-329528
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seaport Therapeutics Q2 net loss $62.6M; cash $427.3M; GlyphAllo Phase 2b on track for 1H 2027
--------------------------------------------------------------------------------

- Net loss of $62.6M for Q2 2026 vs $15.1M in Q2 2025; increase driven by one-time IPO-related stock-based compensation.
- Cash, cash equivalents, and investments of $427.3M as of June 30, 2026, expected to fund operations into 2029.
- Phase 2b BUOY-1 trial of GlyphAllo in MDD on track; topline data expected in 1H 2027.
- Positive Phase 1 data for GlyphAgo: 6.8-fold bioavailability increase vs unmodified agomelatine; Phase 2a in GAD planned for 2H 2026.
- Completed upsized IPO in May 2026 raising $260M gross proceeds; Sharon Mates appointed to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/0001193125-26-329528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-329528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer